LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia

Research output: Contribution to journalArticle

Standard

LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. / Kaderi, Mohd Arifin; Kanduri, Meena; Buhl, Anne Mette; Sevov, Marie; Cahill, Nicola; Gunnarsson, Rebeqa; Jansson, Mattias; Smedby, Karin Ekstrom; Hjalgrim, Henrik; Jurlander, Jesper; Juliusson, Gunnar; Mansouri, Larry; Rosenquist, Richard.

In: Haematologica, Vol. 96, No. 8, 2011, p. 1153-1160.

Research output: Contribution to journalArticle

Harvard

Kaderi, MA, Kanduri, M, Buhl, AM, Sevov, M, Cahill, N, Gunnarsson, R, Jansson, M, Smedby, KE, Hjalgrim, H, Jurlander, J, Juliusson, G, Mansouri, L & Rosenquist, R 2011, 'LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia', Haematologica, vol. 96, no. 8, pp. 1153-1160. https://doi.org/10.3324/haematol.2010.039396

APA

CBE

Kaderi MA, Kanduri M, Buhl AM, Sevov M, Cahill N, Gunnarsson R, Jansson M, Smedby KE, Hjalgrim H, Jurlander J, Juliusson G, Mansouri L, Rosenquist R. 2011. LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. Haematologica. 96(8):1153-1160. https://doi.org/10.3324/haematol.2010.039396

MLA

Vancouver

Author

Kaderi, Mohd Arifin ; Kanduri, Meena ; Buhl, Anne Mette ; Sevov, Marie ; Cahill, Nicola ; Gunnarsson, Rebeqa ; Jansson, Mattias ; Smedby, Karin Ekstrom ; Hjalgrim, Henrik ; Jurlander, Jesper ; Juliusson, Gunnar ; Mansouri, Larry ; Rosenquist, Richard. / LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. In: Haematologica. 2011 ; Vol. 96, No. 8. pp. 1153-1160.

RIS

TY - JOUR

T1 - LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia

AU - Kaderi, Mohd Arifin

AU - Kanduri, Meena

AU - Buhl, Anne Mette

AU - Sevov, Marie

AU - Cahill, Nicola

AU - Gunnarsson, Rebeqa

AU - Jansson, Mattias

AU - Smedby, Karin Ekstrom

AU - Hjalgrim, Henrik

AU - Jurlander, Jesper

AU - Juliusson, Gunnar

AU - Mansouri, Larry

AU - Rosenquist, Richard

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Stem Cell Center (013022011), Hematology/Transplantation (013022014)

PY - 2011

Y1 - 2011

N2 - Background The expression levels of LPL, ZAP70, TCL1A, CLLU1 and MCL1 have recently been proposed as prognostic factors in chronic lymphocytic leukemia. However, few studies have systematically compared these different RNA-based markers. Design and Methods Using real-time quantitative PCR, we measured the mRNA expression levels of these genes in unsorted samples from 252 newly diagnosed chronic lymphocytic leukemia patients and correlated our data with established prognostic markers (for example Binet stage, CD38, IGHV gene mutational status and genomic aberrations) and clinical outcome. Results High expression levels of all RNA-based markers, except MCL1, predicted shorter overall survival and time to treatment, with LPL being the most significant. In multivariate analysis including the RNA-based markers, LPL expression was the only independent prognostic marker for overall survival and time to treatment. When studying LPL expression and the established markers, LPL expression retained its independent prognostic strength for overall survival. All of the RNA-based markers, albeit with varying ability, added prognostic information to established markers, with LPL expression giving the most significant results. Notably, high LPL expression predicted a worse outcome in good-prognosis subgroups, such as patients with mutated IGHV genes, Binet stage A, CD38 negativity or favorable cytogenetics. In particular, the combination of LPL expression and CD38 could further stratify Binet stage A patients. Conclusions LPL expression is the strongest RNA-based prognostic marker in chronic lymphocytic leukemia that could potentially be applied to predict outcome in the clinical setting, particularly in the large group of patients with favorable prognosis.

AB - Background The expression levels of LPL, ZAP70, TCL1A, CLLU1 and MCL1 have recently been proposed as prognostic factors in chronic lymphocytic leukemia. However, few studies have systematically compared these different RNA-based markers. Design and Methods Using real-time quantitative PCR, we measured the mRNA expression levels of these genes in unsorted samples from 252 newly diagnosed chronic lymphocytic leukemia patients and correlated our data with established prognostic markers (for example Binet stage, CD38, IGHV gene mutational status and genomic aberrations) and clinical outcome. Results High expression levels of all RNA-based markers, except MCL1, predicted shorter overall survival and time to treatment, with LPL being the most significant. In multivariate analysis including the RNA-based markers, LPL expression was the only independent prognostic marker for overall survival and time to treatment. When studying LPL expression and the established markers, LPL expression retained its independent prognostic strength for overall survival. All of the RNA-based markers, albeit with varying ability, added prognostic information to established markers, with LPL expression giving the most significant results. Notably, high LPL expression predicted a worse outcome in good-prognosis subgroups, such as patients with mutated IGHV genes, Binet stage A, CD38 negativity or favorable cytogenetics. In particular, the combination of LPL expression and CD38 could further stratify Binet stage A patients. Conclusions LPL expression is the strongest RNA-based prognostic marker in chronic lymphocytic leukemia that could potentially be applied to predict outcome in the clinical setting, particularly in the large group of patients with favorable prognosis.

KW - LPL

KW - RNA-based markers

KW - chronic lymphocytic leukemia

KW - prognosis

U2 - 10.3324/haematol.2010.039396

DO - 10.3324/haematol.2010.039396

M3 - Article

VL - 96

SP - 1153

EP - 1160

JO - Haematologica-The Hematology Journal

T2 - Haematologica-The Hematology Journal

JF - Haematologica-The Hematology Journal

SN - 1592-8721

IS - 8

ER -